LENZ Therapeutics IncLENZ
Price$3.79

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $21.5MTTM through 30 Jun 2026
Net Income -$126MTTM through 30 Jun 2026
Free Cash Flow -$114.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin42.1%
EBITDA Margin-629.6%
Operating Margin-2,331.6%
Net Margin-586.7%

Returns

-44.2%ROE
-40.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio10.40x
Net Debt-$258.4Mnet cash position
Cash & Equivalents$24.2M

Quality Metrics

Altman Z-Score2.01
Piotroski F-Score2 / 9
FCF Margin-532.8%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'24'25
FY2025: $19.1M
Diluted EPS-$4.13TTM
'21'22'23'24'25
FY2025: $-2.85

Dividend

No dividend

Capital Allocation

R&D Spend$3.8M
Capex Intensity2.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.